Inventor · disambiguated record
Zhuchun Wu
Also filed as: WU ZHUCHUN
1 granted patent·12 pending applications·1 citations·filing 2018–2025
17Inventor score
Files withREGENXBIO INC13
Top patents by PatentIndex Score
13 records- 0172US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0271US11613739B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsREGENXBIO INC·Filed 2018·Granted Mar 28, 2023·1 cites·16 claims
- 0367US2025051740A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cellsREGENXBIO INC·Filed 2024·Application pending·0 cites
- 0464US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0563US2024050537A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2023·Application pending·0 cites
- 0657US2025276097A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0755US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 0855US2024425572A1Antibodies and methods of using thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 0947US2019358303A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2018·Application pending·0 cites
- 1046US2020093939A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2019·Application pending·0 cites
- 1140US2021275647A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2019·Application pending·0 cites
- 1237US2021010025A1Treatment of ocular diseases with human post-translationally modified vegf-trapREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1332US2021231560A1Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particlesREGENXBIO INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhuchun Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →